Liu Lilly Y, Nathan Lisa, Sheen Jean-Ju, Goffman Dena
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY, USA.
Int J Womens Health. 2023 Jun 1;15:905-926. doi: 10.2147/IJWH.S366675. eCollection 2023.
Refractory postpartum hemorrhage (PPH) affects 10-20% of patients with PPH when they do not respond adequately to first-line treatments. These patients require second-line interventions, including three or more uterotonics, additional medications, transfusions, non-surgical treatments, and/or surgical intervention. Multiple studies have suggested that patients with refractory PPH have different clinical characteristics and causes of PPH when compared to patients who respond to first-line agents. This review highlights current insights into therapeutic approaches for the management of refractory PPH. Early management of refractory PPH relies on both hypovolemic resuscitation and achievement of hemostasis, with an emphasis on early blood product replacement and massive transfusion protocols. Transfusion needs can be more rapidly and accurately identified through point-of-care tests such as thromboelastography. Medical therapies for the treatment of refractory PPH involve treatment of both uterine atony as well as the underlying coagulopathy, with the use of tranexamic acid and adjunct therapies such as factor replacement. The principles guiding the management of refractory PPH include restoring normal uterine and pelvic anatomy, through the evaluation and management of retained products of conception, uterine inversion, and obstetric lacerations. Intrauterine vacuum-induced hemorrhage control devices are novel methods for the treatment of refractory PPH secondary to uterine atony, in addition to other uterine-sparing surgical procedures that are under investigation. Resuscitative endovascular balloon occlusion of the aorta can be considered for cases of critical refractory PPH, to prevent or decrease ongoing blood loss while definitive surgical interventions are performed. Finally, for patients with critical hemorrhage resulting in hemorrhagic shock, damage control resuscitation (a staged surgical approach focused on restoring normal physiologic recovery and maximizing tissue oxygenation prior to proceeding with definitive surgical management) has been shown to successfully control refractory PPH, with an overall mortality decrease for obstetric patients.
难治性产后出血(PPH)在一线治疗反应不佳时,会影响10%-20%的PPH患者。这些患者需要二线干预措施,包括使用三种或更多宫缩剂、额外的药物、输血、非手术治疗和/或手术干预。多项研究表明,与对一线药物有反应的患者相比,难治性PPH患者具有不同的临床特征和PPH病因。本综述重点介绍了难治性PPH管理的当前治疗方法见解。难治性PPH的早期管理依赖于低血容量复苏和止血,重点是早期血液制品替代和大量输血方案。通过血栓弹力图等即时检验可以更快速准确地确定输血需求。治疗难治性PPH的药物疗法包括治疗子宫收缩乏力以及潜在的凝血功能障碍,使用氨甲环酸和因子替代等辅助疗法。难治性PPH管理的指导原则包括通过评估和处理残留的妊娠产物、子宫内翻和产科裂伤来恢复正常的子宫和盆腔解剖结构。子宫内真空诱导出血控制装置是治疗子宫收缩乏力继发难治性PPH的新方法,此外还有其他正在研究的保留子宫的手术方法。对于严重难治性PPH病例,可考虑进行复苏性血管内主动脉球囊阻断术,以在进行确定性手术干预时预防或减少持续失血。最后,对于因严重出血导致失血性休克的患者,损伤控制复苏(一种分阶段的手术方法,重点是在进行确定性手术管理之前恢复正常生理恢复并最大化组织氧合)已被证明能成功控制难治性PPH,产科患者的总体死亡率降低。